Navigation Links
Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
Date:8/27/2007

ck price, as well as those risks more fully discussed in the "Certain Factors That May Affect Future Results" section of the Company's most recent Quarterly Report on Form 10-Q on file with the Securities and Exchange Commission. In addition, any forward- looking statements represent the Company's views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company does not assume any obligation to update any forward-looking statements.

Quark Pharmaceuticals, Inc The Ruth Group

Gavin Samuels Stephanie Carrington /

SVP, Business Development Elizabeth Scott (investors)

(646) 502-7488 (646) 536-7017 / 7014

gsamuels@quarkpharma.com scarrington@theruthgroup.com

escott@theruthgroup.com

Janine McCargo (media)

(646) 536-7033

jmccargo@theruthgroup.com


'/>"/>
SOURCE Quark Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 2Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 3Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 4Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 5Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 1The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 2The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 3The American Association for Cancer Research Congratulates President Elect on Nobel Prize 58890 4Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 1Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 2Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 3Aurora Health Care Among Six Sites Chosen for National Medicare Collaborative on Geriatric Care 58886 4Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 1Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 2Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 3Federal Stimulus Funding Channels More Than 2440 Million to Fred Hutchinson Cancer Research Center 58882 4
Other Medicine Technology:Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 2Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 3Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 4Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 5Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 6Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 7Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 8Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 9Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 10Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 11Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients 12
Other Medicine News:Health News:MU research team makes progress toward 'printing' organs 2Health News:MU research team makes progress toward 'printing' organs 3Health News:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: 2Health News:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: 3Health News:Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: 4Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 2Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 3Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 4Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 5Health News:NBC 'Today' Co-Host Al Roker to Serve as a National Ambassador for Inspired by Diabetes Campaign to Help Children With Diabetes 6Health News:'AHF/India Cares' Provides Second-line AIDS Drugs to Activists in India 2Health News:'AHF/India Cares' Provides Second-line AIDS Drugs to Activists in India 3Health News:NIH grant advances dentistry school's work on psychosocial stress 2Health News:NIH grant advances dentistry school's work on psychosocial stress 3Health News:Energy Drinks Could Pose Blood Pressure Risks 2